Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer

This article was originally published here

The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual

The post Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply